This investigational drug aims to reduce the number of eosinophils in the esophagus, thus reducing inflammation, pain and swallowing difficulties.

A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis.

CLICK HERE FOR MORE INFORMATION:

The Study

  • Eosinophilic Esophagitis {EoE) is a chronic allergic/immunologic condition where white blood cells, called eosinophils, overpopulate and reside in the esophagus.
  • Eosinophils can release harmful substances that cause inflammation.
  • Chronic inflammation of the esophagus can lead to narrowing, leading to difficulty and/or pain when swallowing.

Study Benefits

  • This investigational drug aims to reduce the number of eosinophils in the esophagus, thus reducing inflammation, pain and swallowing difficulties.

Study Volunteers Must Meet the Following Criteria

  • Male or female
  • Between ages of 18 and 75 years old
  • Must have a previous documented diagnosis of EoE

Study Participant Expectations

  • At the beginning and end of the study, we will ask you to undergo an esophageal biopsy to determine how many eosinophils are present in the tissue

Cost

  • There is no cost to participate
  • If you qualify, you will be compensated up to $625

Register for a Study